Latest Targeted therapy Stories
Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES,
ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report
PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 ASCO-CAP HER2 Testing Guideline updates in breast cancer. Seattle,
Molecularly-Guided Therapies of Critical Importance for Rare Cancers with Fewer Treatment Options IRVING, Texas, Jan.
Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan.
Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan.
Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan.
To Expand Clinical Trial for Advanced Ovarian Clear Cell Carcinoma ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc.
- To fire mitraille at.